Patten Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Patten Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-67	Closed	-$11K	–	533
2018 Q4	$11K	Buy	67 +17	+34%	+$2.95K	0.01%	429
2018 Q3	$10K	Hold	50	–	–	﹤0.01%	523
2018 Q2	$8K	Hold	50	–	–	﹤0.01%	531
2018 Q1	$8K	Hold	50	–	–	﹤0.01%	486
2017 Q4	$7K	Hold	50	–	–	﹤0.01%	519
2017 Q3	$8K	Hold	50	–	–	﹤0.01%	504
2017 Q2	$8K	Hold	50	–	–	﹤0.01%	520
2017 Q1	$6K	Hold	50	–	–	﹤0.01%	513
2016 Q4	$4K	Hold	50	–	–	﹤0.01%	528
2016 Q3	$4.03K	Hold	50	–	–	﹤0.01%	545
2016 Q2	$4.3K	Hold	50	–	–	﹤0.01%	529
2016 Q1	$3.97K	Hold	50	–	–	﹤0.01%	556
2015 Q4	$6.29K	Hold	50	–	–	﹤0.01%	539
2015 Q3	$5.21K	Hold	50	–	–	﹤0.01%	491
2015 Q2	$6.17K	Buy	+50	New	+$6.3K	﹤0.01%	490

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Patten Group's VRTX Position: Q1 2019 in Review

Patten Group sold out of Vertex Pharmaceuticals (VRTX) in Q1 2019, closing a stake of 67 shares — an estimated $11K sold.

Patten Group first reported a position in VRTX in Q2 2015 and held it in 15 quarters. The position peaked at $11K in Q4 2018. 737 funds tracked by Wall St. Rank hold VRTX as of Q1 2019.

Patten Group reported no remaining Vertex Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Patten Group sold 67 Vertex Pharmaceuticals shares in Q1 2019, an estimated $11K.
Patten Group first reported a position in Vertex Pharmaceuticals in Q2 2015 and held it in 15 quarters.
Patten Group's Vertex Pharmaceuticals position peaked at $11K in Q4 2018.
737 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2019.

Based on Patten Group's 13F filing for Q1 2019, filed 14 May 2019.